Stevens Jennifer sold $1K of TLSI
Stevens Jennifer (Chief Regulatory Officer) sold 316 shares of TriSalus Life Sciences, Inc. (TLSI) at $4.39 on 2026-10-05.
How this was made
The 30-second read
Why it matters
The disclosed sale is minor and unlikely to affect TLSI's price or investor sentiment.
Market read
A low‑value insider sale with limited market impact.
What to watch
The officer's role as Chief Regulatory Officer could be relevant if regulatory matters arise, but no such context is provided.
Background
Form 4 filings are mandatory disclosures of insider transactions, providing transparency to investors.
Ticker impact
SEC Form 4 disclosed Chief Regulatory Officer Jennifer Stevens sold 316 shares for $1,387.24 on 2026-10-05.
likely slight pressure as the market prices in the insider sell
Sale amount is under $2k and represents a tiny fraction of total holdings; no broader implications.
Market effects
Minimal; the biotech sector is unaffected by a small insider transaction.
None; the filing is company‑specific.
None
Counterpoint
Even small insider sales can signal concerns, but the size here is negligible.
Key entities
- CompanyTriSalus Life Sciences, Inc.
Biopharmaceutical company focused on rare disease therapies.
- InsiderJennifer Stevens
Chief Regulatory Officer of TLSI.